first look second-quart result ep surpass expect
zoeti thursday morn report better-than-expect second-quart adjust
ep estim also ahead consensu
estim rel model out-performance driven better revenu growth
lower interest expens penni lower tax rate
exhibit addit detail geograph unit state
intern segment slightli outperform estim look across speci
companion outperform estim livestock gener line
exhibit second quarter ep perform rel william blair estim
manag updat ep guidanc includ abaxi acquisit total
manag increas revenu guidanc million midpoint
fall short estim abaxi contribut roughli million previous
estim abaxi full-year revenu million note abaxi purchas signal
aggress expans diagnost like strategi believ
least part due recent currenc fluctuat adjust ep guidanc increas
midpoint exhibit detail
return equiti ttm
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit guidanc rel expect
given better-than-expect quarter slight increas midpoint guidanc bottom top line
full year expect make modest chang increas full-year estim slightli follow morn
ct call believ import topic call broader demand trend impact tariff zoetiss
custom new product pipelin apoquel cytopoint perform continu expect strong
intern growth reiter outperform rate zoeti given reason valuat versu anim health
peer continu steadi underli perform
valuat stock thought wednesday close zoeti trade time estim
compar anim health manufactur peer time high-growth diagnost peer time
maintain outperform rate given solid all-around result reason rel valuat view
updat previou guidancewilliam compani report factset william blair compani estimatesprevi guidanc william blair
august chang estim changedifferencetot net gener administr incl intang oper incom incl incom incom continun op excl extraord incl incom incl extraord excl extraord incl incl extraord net revenu changedifferencedirect gener tax rate incl datau product compani report factset william blair compani estim import disclosur
